Fig. 4: Tumor mutational burden (TMB), circulating lymphocytes, and DCs correlated with objective response rate (ORR) in patients with T4.

A Representative expression of PD-L1 was tested by immunohistochemistry in primary lesion from biopsy specimens, and the combined positive score (CPS) of this patient was 15% (scale bar = 200 µm). B Mutations were analyzed by whole-exome sequencing (WES) of baseline primary tumor lesions from 23 cases. The percentages on the right displayed the proportion of samples harboring a mutation in the genes on the left. The bottom bars displayed ORR from three groups of the T3 stage with PR (n = 11 cases), the T4 stage with PR (n = 8 cases), and T4 stage with SD (n = 4 cases). C Comparison of TMB in baseline tumor samples between the patients with PR (n = 19 cases) and patients with SD (n = 4 cases). D Due to four SD patients being at the T4 stage in this subgroup, we deleted the T3 stage population and further analyzed PR and SD patients with the T4 stage. TMB in baseline tumor samples of patients with PR (n = 8 cases) was higher than those of patients with SD (n = 4 cases). Box plots show distribution of TMB. Lines within box represent the median, the boxes represent quartiles and the whiskers represent the minimum to the maximum. Ns, no statistical significance. Percentage of CD3-CD19+ total B lymphocytes (E) and CD3 + CD19- total T lymphocytes (F) between patients with SD and PR at the T4 stage. Percentage of CD8+ (G) and CD4+ (H) T lymphocytes in total CD3 + CD19- T cells between patients with SD and PR at the T4 stage. Percentage CD123 + CD303+ plasmacytoid dendritic cell (pDC) in total CD11c- cells between patients within SD and patients with PR at the T4a stage (I), and the corresponding statistical analysis graph was shown (J). E, F, G, H, J the statistical significance was tested using a Mann‒Whitney test (two-sided) (SD: n = 4 cases; PR: n = 8 cases), and the line represent the median. Source data are provided as a Source Data file.